MeCure Industries Plc’s latest audited results tell a two-year story of strain and payoff.
In 2024, the pharmaceutical company grew revenue by 45 percent to N46.03 billion, yet profit after tax fell 20 percent to N2.3 billion. Twelve months later, profit surged 183 percent to N6.5 billion as revenue accelerated to N77.69 billion.
The swing from earnings squeeze to breakout reflects a deliberate, debt-funded expansion that collided with Nigeria’s high-interest-rate cycle before beginning to yield returns.
The pressure point in 2024 was financing. To fund new manufacturing capacity, including its Beta-Lactam plant, MeCure leaned heavily on short-term borrowings and commercial papers at a time when the Central Bank of Nigeria was tightening policy aggressively to tame inflation.
Finance costs more than doubled, rising 108 percent from N2.39 billion in 2023 to N4.98 billion in 2024. The company’s interest coverage ratio fell sharply to 1.64x from 3.22x in 2023, indicating that a significant portion of operating profit was consumed by debt servicing. Revenue expanded, but earnings were compressed by the rising cost of capital.
At the same time, MeCure ramped up market penetration efforts. The exit of GlaxoSmithKline from Nigeria’s prescription drug market created a supply gap, particularly in antibiotics. MeCure moved aggressively to position its locally manufactured Amoxyclav and corticosteroids to fill that void.
Selling and distribution expenses jumped 110 percent to N2.4 billion in 2024, reflecting a nationwide marketing and distribution push. In accounting terms, it weighed on profit. Strategically, it represented an attempt to secure shelf space and prescribing loyalty in a rapidly reshaped competitive landscape.
Read also: MeCure eyes N10bn from series 7 Commercial Paper issuance
Operating overheads also climbed. Administrative expenses rose nearly 40 percent to N4.3 billion, driven in part by utilities and diesel costs required to power expanded production lines.
Depreciation charges increased as newly commissioned plants began reflecting on the income statement. While depreciation is non-cash, it lowered reported profit during the transition year.
Imported inflation compounded the challenge. Despite expanding local manufacturing, MeCure remains reliant on imported active pharmaceutical ingredients.
The 2024 naira devaluation lifted input costs significantly. Cost of sales rose 45.5 percent, largely in line with revenue, limiting any improvement in gross margins despite higher volumes.
The result was what appeared to be a paradox: strong top-line growth but weaker bottom-line performance. Profit margins fell to about 5 percent in 2024 from over 9 percent in 2023, underscoring the combined impact of debt servicing, expansion costs, and FX-driven input inflation.
By 2025, however, the financial picture shifted.
Revenue climbed 68.8 percent from N46.02 billion in 2024 to N77.69 billion in 2025, while profit rebounded sharply to N6.5 billion, from N2.3 billion in the prior year. Margins recovered to roughly 8.4 percent, approaching pre-squeeze levels but on a much larger revenue base.
The rebound suggests operating leverage began to take effect. With manufacturing capacity already in place and market penetration efforts largely executed, incremental revenue translated more efficiently into earnings. In effect, 2024 was the investment year; 2025 was the validation year.
Nigeria’s pharmaceutical industry, in general, has been reshaped by currency volatility, multinational retrenchment, and policy tightening. MeCure’s numbers suggest it is attempting to pivot from an import-dependent distributor to a scaled local manufacturer with deeper market reach.
A renewed spike in borrowing costs or fresh FX volatility could pressure margins again. But if scale continues to build and input costs stabilise, the company may be entering a structurally stronger earnings phase.
MeCure Industries is currently the 39th most valuable stock on the Nigerian Exchange (NGX), with a market capitalization of NGN 303 billion, as of February 27, 2026. This is about 0.245 percent of the Nigerian Stock Exchange equity market.
MeCure closed its last trading day (Friday, February 27, 2026) at N75.85 per share on the NGX, recording a 10 percent drop from its previous closing price of 84.25 NGN. MeCure Industries began the year with a share price of N65.20 and has since gained 16.3 percent on that price valuation, ranking it 75th on the NGX in terms of year-to-date performance.
The 2024 profit dip was not merely a downturn; it was the visible cost of expansion during a tightening cycle. The 2025 results indicate that the bet on capacity and market share is beginning to pay off.